Genetic Testing and Inherited Increased Risk of Cancer
People with genetic mutations are often confronted with an abundance of screening protocols that can be overwhelming.
Related Articles
Ruxolitinib May Elicit Skin/Joint, Chronic GVHD Responses
The use of ruxolitinib presented improved rates of skin/joint responses, cGVHD responses, patient-reports, low NRM, and high FFS in patients with refractory sclerotic cGVHD.
Connecting Patients With Multiple Myeloma to Larger Institutions for CAR T-Cell Therapy
Oncology nurses at local and specialized centers can work together to create a pathway for patients throughout CAR T-cell therapy treatment.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck…
Nurse-led High Risk Referral Protocol Improves Risk Communications During Mammography Appointments
Increased use of consultations, breast MRIs, genetic counseling, and other testing in high-risk patients were a direct result from nurse-led high risk referral protocols.
Complex Multidisciplinary Care of an AYA With Ewing Sarcoma
This case demonstrates the pivotal role of a cohesive multidisciplinary team in navigating the complex care of oncology patients from diagnosis, treatment, and posttreatment surveillance.
Rate of Cardiovascular Adverse Events, Myocarditis May Be Low in Trials Assessing ICIs
Even with a low rates of cardiovascular adverse events in patients treated with immune checkpoint inhibitors, cancer care teams should still focus on multidisciplinary approaches…
The Changing Landscape of Clinical Trials in Cancer Care
Although excitement surrounds the constantly changing landscape of cancer care, we have much to learn to keep our practices current.
BCMA/CD19–Targeting CAR T-Cell Therapy Safely Produces Favorable Outcomes in Newly Diagnosed Multiple Myeloma
GC012F, a BCMA/CD19–targeted CAR T-cell therapy, safely produced favorable outcomes in patients with newly diagnosed multiple myeloma after induction therapy.
Two Phase 3 Trials of Pembrolizumab in NSCLC, CSCC to Be Discontinued By Merck
Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.
Companion Diagnostics for Olaparib Plus Abiraterone Acetate Gains FDA Approval in BRCA+ mCRPC
Companion diagnostics have been approved by the FDA for olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer.